United Therapeutics presented four late-breaking phase 3 and interim datasets at the European Society of Cardiology and European Respiratory Society congresses covering pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Ralinepag improved clinical outcomes in lower-risk PAH including the connective tissue disease subgroup, while inhaled treprostinil produced dose-dependent gains in lung function in IPF. A separate screening study indicates standard echocardiography under-detects pulmonary hypertension in patients with interstitial lung disease, delaying treatment in a population where both conditions compound each other.
Key Points
- Ralinepag improved outcomes in lower-risk PAH and connective tissue subgroup
- Inhaled treprostinil showed dose-dependent lung function gains in IPF
- Echocardiography misses pulmonary hypertension in interstitial lung disease patients
Longevity Analysis
Both conditions are routinely mistaken for ordinary aging — breathlessness on stairs, reduced stamina — until the right ventricle is already straining against narrowed, stiffened pulmonary arteries. Correct interpretation of those early signals is the determining variable, and the screening data indicate the current diagnostic tool is not sensitive enough to support it. Dose-response consistency in the inhaled treprostinil data reinforces a broader principle in cardiopulmonary care: sustained, titrated delivery over months, not intermittent intervention, is what shifts ventricular function and preserves the capacity to move oxygen through tissue.
Original published by Longevity.Technology, by Kyle Umipig.